inThought Approvability Index

Allows you to easily assess the probability a compound will be approved for a specific indication.
inThought approvability index provides unique insight into the likelihood a compound will eventually gain regulatory approval by applying a numeric probability and a letter grade to provide a measure of how this drug is progressing compared to historical compounds in the class.

Whether using this forecast as a standalone measurement or as a one of many assessments, you can be assured the inThought Approvability Index is accurate because it is based on a thorough evaluation of the clinical data, the trail designs, and benchmark historical information. All of this feeds into inThought’s proprietary model that assigns points throughout the development process.

inThought Revenue Forecasts

Presents an objective, unbiased forecast of the commercial potential for drugs.
inThought Revenue Forecast provides you with unbiased estimates of future sales of both launched and developmental drugs within a specific indication at both a global and regional level.

You benefit from greater accuracy resulting from our rigorous “top-down” approach that considers addressable patient population, estimates of disease incidence, prevalence, growth rates, and mortality rates along with a detailed assessment of the current and potential competitive landscape.

Adis R&D Insight™

Your window on drug development and innovation worldwide.
Make better strategic decision with insights gained from Wolters Kluwer Pharma Solutions’ leading database of drugs in development worldwide containing over 23,000 detailed assessments of drugs in clinical development as well as launched products throughout their life cycle. This powerful and intuitive resource continually monitors development from company contacts, press releases, international conferences, company websites, and more than 1,300 medical journals to provide the in-depth scientific evaluations and commercial overviews needed to quickly and accurately answer key questions in market and competitive analysis.

• Monitor the progress of competitors’ R&D programs
• Evaluate the strengths and weaknesses of compounds
• Assess the commercial potential of upcoming products
• Access key scientific data to support licensing opportunities
• Review success/failure rates of companies or technologies
• Track the development of more than 3,000 pharmaceutical and biotech companies

Back to the top ^

Adis Clinical Trials Insight®

The new standard in rapid evaluation of clinical trial evidence.
Quickly find, compare, and evaluate the precise clinical trial evidence required to make informed strategic decisions throughout the drug development process.  With history dating back to 1990 and continually drawing from articles published in the top 1300 medical journals, presented at the top 100 medical meetings, and registered trials on government, university, industry, and public websites, the Adis Clinical Trials Insight database delivers a comprehensive view of the past, present, and future clinical trials effecting the standard of care.

• Quickly and accurately locate relevant clinical trials
• Identify key study messages emerging from clinical studies
• Discover trials reporting new and important clinical evidence
• Assess the merits of combination therapies
• Map out clinical trial outcomes
• Uncover clinical evidence presented at recent meetings

At-A-Glance understanding of study results, messages, endpoints, design, and phase as well as investigator data, sponsor information, and subject inclusion/ exclusion criteria using the extensive charting tools integrated into the product.

Pharmaceutical Audit Suite (PhAST)

Gain access to prescription and sales volumes for all therapeutic classes and products at the product, form, strength, manufacturer, and ndc-11 levels to track and size the market potential of brands nearing patent expiration or new product launches.  This web-based product is the most cost effective solution in its industry, and it is easy for users to log-in, generate reports, save reports (for easy generation at any time) and export them into Microsoft Excel.  With its low subscription price, the service can provide a strong return-on-investment and pay for itself in a matter of months.

• Both Retail and Mail Order data
• Access to data for ALL Corporation/Manufacturers
• Access to ALL therapeutic classes and products included
• Ability to pull data at the NDC level
• Ability to view Managed Care data at the payment level. Third Party/Cash/Medicaid
• Access to lower levels of geography i.e. Metropolitan Statistical Area (MSA), Demographic Market Area (DMA), Census district and State
• Unlimited access to building reports with NO additional charges per report
• Dollars and units available in the same report. No need to run two reports
• Eliminate the need to recreate valuable reports with subscriptions that run automatically
• Different products for different needs - PhAST Weekly, PhAST Monthly, PhAST Institution and PhAST Integrated
• Access via the internet from any location
• Weekly Data available Monday 6:00 a.m.